Baseline sBCMA and response to treatment. (A) Teclistamab. (B) Talquetamab. Data cutoff dates for response were 24 December 2020 (MajesTEC-1) and 2 January 2021 (MonumenTAL-1); median (range) shown. Patients were categorized as responders or nonresponders based on their best responses. IV, intravenous; SC, subcutaneous.